Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003892 · ClinicalTrials.gov registry record · Phase 2
ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer
A Phase 2 study, sponsored by NCIC Clinical Trials Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00003892 is a Phase 2 study that has completed, run by NCIC Clinical Trials Group. The registered enrollment target is 22 participants.
The verdict
NCT00003892, a Phase 2 study, has completed, sponsored by NCIC Clinical Trials Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ISIS 5132 in treating patients who have metastatic or recurrent ovarian cancer that has not responded to previous chemotherapy.
Interventions
- DRUG ISIS 5132
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 1999-02-01 |
| Est. Completion | 2008-09-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003892
The ClinicalTrials.gov registry entry for NCT00003892 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NCIC Clinical Trials Group, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ISIS 5132 is the first listed.
NCT00003892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003892 about?
NCT00003892 is a clinical study titled "ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ISIS 5132 in treating patients who have metastatic or recurrent ovarian cancer that has not responded to previous chemotherap...
What is the current status of trial NCT00003892?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 1999-02-01. Estimated completion is 2008-09-22.
What interventions are being tested in trial NCT00003892?
The interventions under investigation include: ISIS 5132 (DRUG).
Who is sponsoring clinical trial NCT00003892?
This trial is sponsored by NCIC Clinical Trials Group, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.